Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00165139 · ClinicalTrials.gov registry record · Phase 2
Intensive Chemo-Radiotherapy With Peripheral Blood Progenitor Cell Rescue for Children With Advanced Neuroblastoma and Sarcomas
A Phase 2 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT00165139 is a Phase 2 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 20 participants.
The verdict
NCT00165139, a Phase 2 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
The main purpose of this study is to determine the short and long term side effects of a very intensive treatment, which includes combinations of chemotherapy drugs followed by radiation therapy and two transplants supported by peripheral blood progenitor cells (stem cells), for children with advanced stage neuroblastoma and sarcomas.
Interventions
- DRUG Cyclophosphamide
- DRUG Cisplatin
- DRUG Vincristine
- DRUG Adriamycin
- DRUG Etoposide (VP-16)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 1996-01 |
| Est. Completion | 2009-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00165139
The ClinicalTrials.gov registry entry for NCT00165139 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT00165139 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00165139 about?
NCT00165139 is a clinical study titled "Intensive Chemo-Radiotherapy With Peripheral Blood Progenitor Cell Rescue for Children With Advanced Neuroblastoma and Sarcomas". The main purpose of this study is to determine the short and long term side effects of a very intensive treatment, which includes combinations of chemotherapy drugs followed by radiation therapy and two transplants supported by peripheral blood progenitor cells (stem cells), for children with advanc...
What is the current status of trial NCT00165139?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 1996-01. Estimated completion is 2009-02.
What interventions are being tested in trial NCT00165139?
The interventions under investigation include: Cyclophosphamide (DRUG), Cisplatin (DRUG), Vincristine (DRUG), Adriamycin (DRUG), Etoposide (VP-16) (DRUG).
Who is sponsoring clinical trial NCT00165139?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.